Publicaciones en las que colabora con Salvador Martín Algarra (6)

2020

  1. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

2018

  1. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

  2. Dermatología

    Guía inmunotoxicidad: diagnóstico y manejo de los efectos secundarios asociados a inmunoterapia en oncología (EUNSA. Ediciones Universidad de Navarra, S.A.), pp. 36-51

2008

  1. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma

    Oncology, Vol. 74, Núm. 1-2, pp. 12-16

2007

  1. Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab

    Clinical and Translational Oncology, Vol. 9, Núm. 2, pp. 119-120

2004

  1. ERK 1/2 is activated in non-small-cell lung cancer and associated with advanced tumours

    British Journal of Cancer, Vol. 90, Núm. 5, pp. 1047-1052